Published in final edited form as:

Cell Mol Life Sci. 2015 March ; 72(6): 1161–1173. doi:10.1007/s00018-014-1790-1.

Protective role of Hemeoxygenase-1 in Gastrointestinal Diseases

Marisol Chang, Jing Xue, Vishal Sharma, and Aida Habtezion

Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University
School of Medicine, Stanford, California, 94305

Abstract

Disorders and diseases of the gastrointestinal system encompass a wide array of pathogenic mechanisms as a result of genetic, infectious, neoplastic, and inflammatory conditions. Inflammatory diseases in general are rising in incidence and are emerging clinical problems in gastroenterology and hepatology. Hemeoxygenase-1 (HO-1) is a stress-inducible enzyme that has been shown to confer protection in various organ-system models. Its downstream effectors, carbon monoxide and biliverdin have also been shown to offer these beneficial effects. Many studies suggest that induction of HO-1 expression in gastrointestinal tissues and cells plays a critical role in cytoprotection and resolving inflammation as well as tissue injury. In this review we examine the protective role of HO-1 and its downstream effectors in modulating inflammatory diseases of the upper (esophagus and stomach) and lower (small and large intestine) gastrointestinal tract, the liver, and the pancreas. Cytoprotective, anti-inflammatory, anti-proliferative, anti-oxidant, and anti-apoptotic activities of HO-1 make it a promising if not ideal therapeutic target for inflammatory diseases of the gastrointestinal system.

Keywords

Hemeoxygenase-1; carbon monoxide; biliverdin

Introduction

The biological importance of hemeoxygenase (HO) originates from its function as the rate-limiting enzyme in heme catabolism. Heme is oxidatively cleaved by the HO system into equimolar quantities of carbon monoxide (CO), biliverdin, and Fe^{2+} [1]; and in a coupled reaction biliverdin is rapidly converted into bilirubin via biliverdin reductase [2]. Three distinctive HO isoforms have been identified and although they catalyze the same biochemical reaction they are the products of different genes with different expression patterns in cells and tissues [3]. HO-3 (33 kD) is a poor heme catalyst that has been found only in rat brain with no activity reported in humans [4,5]; HO-2 (36 kD) which contributes to cell homeostasis is constitutively expressed in many tissues including neuronal and testicular tissues [6,7]; whereas HO-1 (32 kD), also known as heat shock protein-32

(Hsp32), is stress-inducible and expressed at a relatively low level in most tissues. In addition to its substrate heme, HO-1 is upregulated by heavy metals [8] and stimuli that cause oxidative stress such as heat shock [9], ischemia, hemorrhagic shock [10], reactive oxygen species (ROS) [11], radiation, and hypoxia [12]. Many reports have also shown that inflammatory mediators such IL-1, TNF- α , LPS, ROS and reactive nitrogen species (RNS) are able to upregulate HO-1 in vitro [13,14].

HO-1 induction is usually associated with a protective response [15]; classically the beneficial nature of HO is attributed to its ability of removing free heme, which has cytotoxic effects [5]. However, new evidence indicates that although HO-1 as such does not directly catalyze an antioxidant reaction, its upregulation, and the production of CO and biliverdin, influences many biological events linked to a cytoprotective and anti-inflammatory response against oxidative stress [16–18]. For instance CO is believed to act as a signaling molecule in a similar manner as nitric oxide (NO), with anti-inflammatory and anti-apoptotic properties [19,20]. The anti-inflammatory actions of CO have been proposed to be mediated through p38 mitogen-activated protein kinase (MAPK) pathway [19,21]. Biliverdin and bilirubin are reducing agents with antioxidant properties and have the ability to efficiently scavenge proxyl radicals and inhibit lipid peroxidation [22]. Although biliverdin is rapidly converted to bilirubin and has a short half-life, in an recycling process bilirubin as a potent antioxidant oxidizes itself back to biliverdin [23,24]. Treatment with biliverdin decrease mRNA expression of inducible nitric oxide synthase (iNOS), cyclooxygenase 2, and the inflammatory cytokines IL-6 and IL-1 β , as well as decrease neutrophil infiltration into the jejunal muscularis in rat model of small intestinal transplants [25]. Moreover, biliverdin is an endogenous ligand of the aryl hydrocarbon receptor (AhR), which upon activation protects against experimental acute pancreatitis by induction of IL-22 [26]. Similarly; Fe²⁺ is involved in gene regulation including that of NO synthase (NOS). Although potentially toxic, Fe²⁺ leads to the opening of channels that export Fe²⁺ from the cells inducing the upregulation of ferritin, an iron storing protein which protects cells against oxidant damage by oxidation of low-density lipoproteins [27,28].

The beneficial effects of HO-1 have been demonstrated in HO-1 deficient mice models which have atypical innate and adaptive immune responses with a general pro-inflammatory response displaying a T helper 1 (Th1)-type cytokine profile (IL-1, IFN- γ , TNF- α , IL-6) [29]. HO-1 deficient mice develop chronic inflammation, and are vulnerable to endotoxin sepsis [30] and have defective expression of interferon- β [31]. In addition, ablation of the HO-1 gene results in alteration of the endothelial monolayer making it more susceptible to apoptosis and denudation from the extracellular matrix [32,33]. On the other hand, HO-2 deficient mice have intact immune regulation but have defects in their central and autonomic nervous system [34]. Many of the clinical hallmarks observed in HO-1 deficient mice are consistent with those found in HO-1 deficient patients. HO-1 deficiency in both in human and mice is either lethal before birth or results in death at early age; survivors present with anemia, erythrocyte fragmentation and iron deposition [35]. In humans HO-1 deficiency is characterized by hemolysis, disseminated intravascular coagulation, nephritis and asplenia [35,36]. In the first human reported case of HO-1 deficiency an infant, born to parents without clinical manifestation each of whom had a partial deletion of the HO-1 gene in different alleles, had severe inadequate HO-1 expression with affected phenotype that

proved to be fatal [35]. The afflicted patient had marked growth and developmental retardation associated with erythrocyte fragmentation and abnormal coagulation/fibrinolysis system since early age [35]. In a different case of HO-1 deficiency, the characteristic symptoms manifested later in life but the clinical outcome was the same as in the first patient [36]

HO-1 Regulation

Currently the transcriptional regulation of the HO-1 gene is attributed to two transcription factors: nuclear erythroid 2-related factor-2 (Nrf2) and the heme binding protein Bach1 [37,38]. Nrf2 plays a crucial role in cytoprotection and contains an activation domain that initiates HO-1 transcription, whereas Bach1 represses HO-1 transcription by competing with Nrf2 [37,38]. Other molecules are also associated with HO-1 upregulation; for instance MAPK signaling is involved in HO-1 induction [39] and the phosphatidylinositol-3 kinase (PI3K)/Akt signaling modulates HO-1 activity by phosphorylation of Ser-188 [40]. It was also shown that the anti-inflammatory cytokine IL-10 induces HO-1 expression via a p38 MAPK-dependent pathway [21]. Upregulation of HO-1 in turn amplifies the effects of IL-10. In activated macrophages, HO-1 and CO mediate IL-10 inhibition of iNOS expression and NO production [21]. In addition, HO-1 and IL-10 work in conjunction to suppress the expression of the pro-inflammatory cytokine TNF- α [21]. The suppressive effect of IL-10 on TNF- α production was reversible with zinc protoporphyrin (ZnPP), an HO-1 inhibitor [21].

The regulation of HO-1 response to an inflammatory stimuli is further demonstrated via its association with an HO-1 gene promoter microsatellite (GT)(*n*) dinucleotide repeat polymorphism [41] and a single nucleotide polymorphism (SNP) A(-413)T in the promoter [42,43]. In humans the GT length polymorphism in the HO-1 promoter is associated with the strength of HO-1 response to a given stimulus. Individuals with short GT repeats are reported to have a lower risk of necrotizing acute pancreatitis [44], chronic pulmonary emphysema [45], rheumatoid arthritis [46], restenosis after balloon angioplasty [47], coronary artery [48], and other diseases [41]. In addition to the (GT)(*n*) polymorphism, the A(-413)T SNP has been identified as a functionally relevant variation of the HO-1 gene; even more important for HO-1 promoter activity than the (GT)*n* polymorphism [42,43]. The A(-413)T genotype of HO-1 is associated with an increased incidence of hypertension in women [42] and reduced the incidence of ischemic heart disease [43], possibly due to the high expression of HO-1.

HO-1 Expression

At the cellular level, HO-1 is highly expressed in Kupffer cells in the liver [49], spleen macrophages [50] and dendritic cells [51]. HO-1 upregulation in these cells in response to LPS attenuates the expression of various pro-inflammatory genes [52,53]. Likewise pharmacological induction of HO-1 in dendritic cells alters their maturation state and interaction with other cells [51,54]. For instance HO-1 expression in dendritic cells is essential for the function of T cells influencing the proliferation of both effector and regulatory CD4 T cells [55,56]. Accumulating evidence shows that HO-1 is involved in multiple functions of macrophages including infiltration, differentiation and polarization.

HO-1 induction is essential for monocyte/macrophage early infiltration to damaged tissues. Induction of HO-1 by hemin is associated with upregulation of chemokines (MCP-1/ MIP-1 α) and recruitment of HO-1⁺ monocyte/macrophages into the pancreas [57]. HO-1 expression is increased during myeloid progenitor cell differentiation, and is critical for myeloid cells differentiation into macrophages [58]. In addition, up-regulation of HO-1 contributes to alternative activation of macrophage that play a critical role in anti-inflammation and tissue repair [59]. At a tissue level HO-1 is constitutively expressed in the liver, gastric, intestinal, and colonic mucosa [60–62]. Expression of HO-1 is increased during inflammation and gastrointestinal injury such as in gastric ulcers [63], radiation enteritis [64], inflammatory bowel disease [65–67], and liver fibrosis [68].

In this review we provide an overview of the protective roles of HO-1 in diseases of the upper (stomach and esophagus) and lower (small and large intestine) gastrointestinal tract, the pancreas and the liver.

HO-1 and Diseases of the Esophagus and Stomach

It is suggested that HO-1 and CO may play a role in the maintenance of proper function of the lower esophageal sphincter (LES) [69,70]. Whenever the LES is dysfunctional due to weakness or improper relaxation, the contents of the stomach rise up into the esophagus, leading to reflux of gastroduodenal contents and subsequent gastroduodenal reflux disease and/or esophagitis [71]. CO is believed to play a role as a peripheral messenger due to its relaxant effect on the circular LES muscle [70]. The expression of CO in the LES [70,69] is linked to HO-1 activity since CO production was blocked with the use of HO-1 inhibitor ZnPP [70]. Reflux of duodenal juice was found to be necessary to induce the oxidative damage leading to HO-1 upregulation in rats that underwent esophagoduodenal anastomosis (EDA); a model for esophagitis due to duodenoesophageal reflux into the distal esophagus [72].

Users of Non-steroidal anti-inflammatory drugs (NSAID) have a greater risk of developing esophagitis, esophageal and gastric ulcers [73]. The beneficial effect of HO-1 expression on esophageal and gastric ulcers has also been demonstrated in models of NSAIDs such as indomethacin and ketoprofen mediated injuries [74–76]. In an indomethacin-induced gastric ulcer model there was increased tissue expression of IL-6 and TNF- α [74]. HO-1 induction with cobalt protoporphyrin (CoPP) ameliorated the disease by reducing gastric inflammation, tissue neutrophil activation and the expression of pro-inflammatory cytokines [74]. Furthermore, in this model HO-1 upregulation, via activation of Nrf2, was found to protect the gastric mucosa by inhibiting apoptosis [75]. Conversely, HO inhibitor tin mesoporphyrin (SnMP) resulted in exacerbation of gastric lesions and increased apoptosis [75]. In ketoprofen-induced peptic ulcer catechin, a dietary polyphenol antioxidant, was protective against epithelial cell injury by inducing the expression of HO-1 via modulation of Nrf2 and inhibition of oxidative damage [76].

Numerous studies have shown that the cytoprotective effects observed by many pharmacological agents used in upper gastric diseases such as, polaprezinc [77], eupatilin [78] and lansoprazole [79] may be in part mediated via HO-1 upregulation. In cultured

esophageal epithelial cells, there was a dose and time dependent expression of HO-1 in response to eupatilin in vitro and in esophageal epithelium of rats in vivo [80]. Eupatilin-induced HO-1 expression in the cultured esophageal epithelial cells was mediated by nuclear translocation of Nrf2 and by ERKs and PI3K/Akt signaling [80]. In addition, eupatilin prevented cytotoxic action of indomethacin.

HO-1 induction has also been reported to have a beneficial effect in diabetic gastroparesis, a condition with delayed gastric emptying due to complications of diabetes mellitus. In diabetic gastroparesis there was a decrease in HO-1⁺ CD206⁺ macrophages and an increase in oxidative stress that was associated with low expression of the receptor tyrosine kinase *KIT* in interstitial cells of Cajal (ICC) resulting in delayed gastric emptying [78,81]. In a non-obese diabetic (NOD) model of diabetic gastroparesis, hemin treatment protected ICC by decreasing reactive oxygen species and restoring *KIT* expression [82]. In addition, hemin treatment led to repopulation of HO-1⁺ gastric CD206⁺ macrophages and a phenotypic switch from pro-inflammatory M1 macrophages to wound healing inducer M2 macrophages [59]. The increased number of HO-1⁺ expressing gastric macrophages was associated with normalization of gastric emptying [59]. Thus HO-1 expressing CD206⁺ macrophages appear to play an important role in preventing delayed gastric emptying in diabetic mice.

HO-1 and Diseases of the Small & Large Intestine

The expression of HO-1 in intestinal tissue is localized in mononuclear cells of the submucosal layer [83] and epithelial cells in the human duodenal mucosa [61,60]. Although HO-1 is constitutively expressed in intestinal epithelial cells, HO-1 inducers appear to ameliorate mucosal injury by decreasing infiltrating inflammatory cells such as neutrophils and lymphocytes [65]. HO-1 induction has been shown to be beneficial in models of small intestinal injury. For instance, in indomethacin mediated injury, pharmacologic induction of HO-1 by lansoprazole [84,85] and sulforafane [86] resulted in inhibition of intestinal injury, which was reversed by HO-1 inhibition with tin protoporphyrin (SnPP) [84].

CO mediates many of the biological actions of HO-1; CO releasing molecules (CORMs) were shown to lessen intestinal injury during post-operative ileus [39], indomethacin injury [85] and sepsis [87]. Postoperative Ileus is the transient impairment of bowel motility usually as a result of a major abdominal surgery. Pre-treatment with CO-RMs reduced the development of postoperative ileus in mice [39]. The protective effects were mediated in part via induction of HO-1 expression and activity through modulation of the MAPK signaling pathway (p38 and ERK1/2) [39]. In addition CO-RMs reduced oxidative stress and suppressed the inflammatory response associated with intestinal manipulation [39]. The beneficial effect was abrogated by chromium mesoporphyrin (CrMP), an HO-1 inhibitor, which aggravated the intestinal injury [39]. Similarly in an indomethacin induced small intestinal ulceration, pretreatment with CORMs reduced the severity of injury by inhibition of iNOS expression through upregulation of HO-1/CO in the mucosa [85]. Likewise this protective effect was reversible with the use of HO-1 inhibitor SnPP [85]. Furthermore the beneficial role of HO-1 and CO during sepsis, a complex syndrome characterized by both infection and a systemic inflammatory response, was demonstrated with the use of CO-RMs [87]. Administration of CO-RMs 6 hours after sepsis onset decreased bacterial counts,

increased bacterial phagocytosis and reduced mortality in HO-1 deficient mice highlighting the importance of CO as a protective downstream effector of HO-1 [87].

Ischemia/Reperfusion Injury

Ischemia/reperfusion (I/R) injury of the gut occurs frequently due to interruption and reintroduction of blood supply; it has been shown that induction of HO-1 has anti-inflammatory and cytoprotective effects in I/R mediated small intestinal injuries [88–90]. Administration of CoPP before intestinal I/R induces HO-1 and reduces I/R injury [91]. Other agents such as glutamine, a major fuel for enterocytes, protect the intestine from I/R injury by inducing the expression of HO-1 in the intestinal mucosa of villous epithelial cells, crypts, and muscular layers and by inhibiting inflammatory cytokines [92]. In a similar manner, pyrrolidine dithiocarbamate improves the outcome of I/R injury by inducing HO-1 production and enhancing perfusion in the microvasculature [93]. Ablation of the HO-1 gene in mice exacerbates I/R injury [94,95], conversely mice that over-express HO-1 due to Bach1 deficiency have a damped response to I/R mediated injury [96]. In addition, the products of HO-1 activity have also been found to ameliorate intestinal I/R injury. CO inhalation at a low concentration attenuates the remote intestinal inflammatory response caused by hindlimb I/R [97,98]; and protects against I/R injury of intestinal grafts during prolonged cold preservation [99]. Similarly, biliverdin and bilirubin act as potent cytoprotective agents during I/R [98,100].

HO-1 expression has also been found to be increased in patients with ischemic colitis a condition in which there is inadequate blood flow to the large intestine due to narrowed or blocked blood vessels leading to colonic inflammation [101].

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) comprises of Crohn's disease and ulcerative colitis. While ulcerative colitis is limited to the colon and rectum, Crohn's disease can affect any part of the gastrointestinal tract from the mouth to the anus, although over a third of Crohn's disease patients have disease involving the terminal ileum [102]. HO-1 mRNA and protein are increased in inflamed colonic mucosa of IBD patients [65,67] and in colitis mouse models [66,67,103]. Upregulation of HO-1 in the large intestine by hemin [66,104], heme [105] and CoPP [106,65] results in a better outcome in experimental colitis. HO-1 expression and activity were increased in the damaged colonic tissue following the acute model of 2,4,6-trinitrobenzene sulfonic acid (TNBS) colitis and it is believed that the protective effect of HO-1 could be the result of radical scavenging and inhibition of NO production and iNOS expression since HO-1 induction by hemin lowered iNOS mRNA and protein expression in the affected colon [66]. Similarly, HO-1 induction with CoPP was protective in the dextran sulfate sodium (DSS) mouse model of colitis [65]. On the contrary the use of HO-1 inhibitors reversed the beneficial effects of HO-1 induction. For instance, in the TNBS colitis model, administration of the HO inhibitor SnMP resulted in reduction of HO-1 activity and increased colonic damage [66]. In the same way, treatment with the HO inhibitor Znpp enhanced intestinal inflammation and increased the disease severity score in the DSS colitis model [103]. Furthermore, mice deficient of the HO-1 transcription factor Nrf2, have low HO-1 expression and are more susceptible at developing colitis in the DSS

model [107]. In contrast, mice deficient of the Bach1 transcription factor have higher expression of HO-1 mRNA and protein in colonic mucosa and have significantly attenuated colonic inflammation after induction of TNBS colitis [108]. The expression of HO-1 from Bach1-deficient mice was localized mainly in F4/80⁺ and CD11b⁺ macrophages which presented M2-type markers such as, Fizz-1, Ym1, and MRC1 [108]. Further experiments indicated that transfer of these macrophages into wild-type mice, inhibited TNBS-induced colitis [108].

The therapeutic benefits of HO-1 in colitis can be attributed to the effect of HO-1 activation: biliverdin [106] and CO [109,110]. In a DSS-induced acute colitis model, administration of biliverdin has a protective effect comparable with the one seen with treatment of HO-1 inducer CoPP [106]. In addition, in the chronic Th1 mediated IL-10 deficient mice model of colitis, CO at a low concentration diminishes chronic intestinal inflammation by inducing HO-1 expression [109]. It was shown that CO acts upon macrophages by altering IFN- γ signaling and by inhibiting activation of IL-12 p40 and iNOS after LPS/IFN- γ stimulation through selective inhibition of IRF-8 [109]. Similarly the beneficial effects of CO and HO-1 induction were also demonstrated in a Th2 mediated TCR α deficient mice model of colitis by increasing the expression levels of the anti-inflammatory cytokines IL-10 and IL-22 [110]. HO-1 upregulation has also been attributed to the efficacy of current IBD therapies such as 5-amino salicylic acid (5-ASA) [111]. Intracolonic administration of 5-ASA in a TNBS model of colitis increased HO-1 expression levels, reduced colonic injury, decreased myeloperoxidase activity and TNF- α levels and these effects were abolished with HO-1 inhibitor ZnPP [111].

Necrotizing Enterocolitis

HO-1 activity has also been linked to the development of necrotizing enterocolitis (NEC) [112] a condition in premature or low weight infants that mostly affects the distal ileum and less commonly the right colon or upper small bowel [113]. Mice heterozygous for the HO-1 gene (HO-1^{Het}) have abnormal intestinal morphology, are predisposed to intestinal injury and enhanced apoptosis [112]. Due to the fact that HO-1^{Het} mice have deficient upregulation of HO-1, they have exaggerated inflammatory response observed by increased expression of IL-1 β , P-selectin, and MMP2, resulting in higher incidence and onset of NEC [112].

Radiation Enteritis

Radiation enteritis is a condition in which there is mucosal damage to the lining of the intestine with infiltration of activated inflammatory cells during or after ionizing radiotherapy to the abdomen, pelvis, or rectum [114]. HO-1 induction by glutamine protects against abdominal radiation-induced damage to the intestinal tissues in a rat model by decreasing myeloperoxidase (MPO) and caspase-3 activity, and malondialdehyde (MDA) levels which leads to reduction of tissue inflammation and suppression of apoptosis [115]. HO-1 inhibition by ZnPP in irradiated rats worsened the intestinal damage [115]. In addition, in a rat model of abdominal radiation it was proposed that the protective effect of octreotide (OCT), the synthetic analogue of somatostatin, against radiation-induced intestinal damage [116] was in part mediated by modification of the inflammatory response and induction of HO-1 expression [117].

HO-1 and Diseases of the Pancreas

Pancreatitis is an inflammatory disease that is clinically categorized into acute and chronic. Acute pancreatitis (AP) is one of the most frequent gastrointestinal causes of hospital admission in the United States. AP ranges from mild transient self-limited inflammatory reaction to severe high mortality disease state with multiple organ dysfunction syndrome (MODS) [118]. Chronic pancreatitis (CP), although lower in incidence, significantly reduces patients' quality of life [119]. CP is characterized by inflammation, fibrosis, exocrine and/or endocrine insufficiency as well as chronic abdominal pain [120]. CP can be driven by recurrent acute pancreatitis and is a risk factor for the development of pancreatic ductal adenocarcinoma (PDAC) [121]. Gallstone and excessive alcohol use are the most common causes of AP. In addition to alcohol, genetics, obesity and smoking have been identified as important independent risk factors for pancreatitis [119]. However, the current therapeutic options in the treatment of both AP and CP are limited to supportive care and active therapies that can alter outcome and natural cause of these diseases are urgently needed. Several independent groups have shown that HO-1 activation and its downstream effectors (CO and biliverdin) have the ability to ameliorate experimental AP [122,26,123].

HO-1 is upregulated both in animal models of AP [124] and hospitalized AP patients [125]. HO-1 is induced in both mild and severe experimental AP induced by cerulein and feeding a choline-deficient diet (CDD) respectively. Intraperitoneal hemin administration dramatically increases peritoneal and pancreas macrophages that overexpress HO-1 and was responsible for the beneficial therapeutic effect of hemin [126]. Pilot and proof-of-concept study in patients hospitalized with AP demonstrated that HO-1 was upregulated in peripheral blood mononuclear cells (PBMCs), primarily in monocytes, during the course of pancreatitis and decreased significantly upon recovery [125]. These findings showed an association between reversible monocyte HO-1 upregulation and clinical improvement of AP. Furthermore, the beneficial effect of Panhematin (FDA-approved hemin formulation) was demonstrated in established experimental AP, supporting a potential use of hemin in clinical trial for pancreatitis in the future [127]. More recently, HO-1 based gene therapy (adenoviral transfer of HO-1) showed beneficial effects in experimental severe AP [128]. Most of the studies demonstrate that HO-1 based therapy to be mediated mainly via macrophages. HO-1 is induced in macrophages as early as 2h after intraperitoneal and intravenous hemin or Panhematin administration. Recruitment of monocytes/macrophages into the inflamed pancreas likely starts resolution phase of pancreatitis by decreasing pro-inflammatory cytokines (TNF α , IL-6 and IL-1 β) and by increasing anti-inflammatory cytokines such as IL-10 [127,126]. In this manner, HO-1 contributes to a shift of macrophage polarization from classically (M1) to alternative activated (M2) phenotype, which play a critical role in anti-inflammation and tissue repair [129]. Interestingly, recently it was reported that the length of the GT repeats in the HO-1 gene promoter polymorphism is associated with the development of severe and necrotizing AP [44]. Patients with SS (GT)(n) genotype have higher HO-1 expression and may be protected against the development of severe pancreatic injury and fatal outcomes once the inflammatory response is initiated [44].

A wide array of evidence suggests that protective properties of HO-1 can also be mediated via its effector molecules---carbon monoxide (CO) and biliverdin (BV) [122,26,123]. CO

deliverance is achieved mainly through inhalation and CO-RMs. CO or CO-RMs have been shown to protect against experimental AP via inhibition of NF- κ B signaling [130]. Recently, our group showed that CO-RMs ameliorate experimental AP via inhibition of macrophage TLR4 expression and activation. To avoid potential side effects of systemic CO or CO-RMs, a novel therapeutic approach was taken by showing therapeutic potential of CORM-primed monocytes adoptive transfer in experimental AP [123]. Biliverdin is another product of HO-1 activation with promising future clinical use in AP. In a recent report, biliverdin attenuated experimental AP through activation of the aryl hydrocarbon receptor (AhR)/IL-22 signaling pathway [26].

Furthermore, specific induction of HO-1 might also be applicable for treatment of chronic pancreatitis. Pancreatic stellate cells (PSCs) play a cardinal role during pancreatic fibrosis development [131]. Therefore, the suppression of PSCs growth represents a therapeutic option for the treatment of pancreatic fibrosis. In addition, it was shown that HO-1 induction by curcumin inhibited pancreatic stellate cell proliferation [132]. These findings have been extended in a more recent report, in which PSCs proliferation was inhibited by CORM2 via activation of p38 MAPK/HO-1 pathway, indicating a therapeutic potential of CO carriers in the treatment of pancreatic fibrosis [133]. Although in vitro data implicate a potential influence of HO-1 on pathogenesis of CP, the function of HO-1 or its therapeutic use in development of CP still needs to be further confirmed by in vivo experimental and clinical studies, as the role of HO-1+ macrophages in CP remains unknown.

HO-1 and Diseases of the Liver

Liver damage due to I/R injury occurs often during shock and surgical procedures such as liver resection or transplantation. The use of CoPP, an HO-1 inducer, or gene therapy with a recombinant adenovirus encoding HO-1 cDNA can prevent severe I/R in a steatotic rat liver model of ex vivo cold I/R injury [134]. The protective effect of HO-1 was abrogated after administration of the HO-1 inhibitor ZnPP [134]. Similarly in a mouse model of segmental hepatic I/R the administration of CoPP prior to the I/R protects the liver from hepatic parenchymal and apoptotic injury via a NF- κ B pathway and induction of endoplasmic reticulum stress transcriptional C/EBP homologous protein (CHOP) [135]. It was also found that remote ischemic preconditioning (RIPC) protects against warm liver I/R injury via HO-1 upregulation [136]. In this model HO-1 induction by hemin increased autophagy via a p38-MAPK mediated pathway whereas HO-1 inhibition by ZnPP resulted in hepatic damage or cell death [136]. Similarly, HO-1 upregulation in the liver in response to sepsis or LPS stimulation limits hepatocyte death and protects against liver damage via autophagy [137]. This was confirmed with HO-1 deficient mice or pharmacologic inhibition of HO-1 by SnPP in which HO-1 deficiency resulted in interruption of autophagic signaling resulting in hepatic injury and apoptosis [137].

Orthotopic liver transplantation (OLT) is used as treatment for end-stage liver diseases [138]; however I/R to the graft leads to allograft rejection a condition mediated by apoptosis via the CD95/FasL (CD95L) pathway [139]. In a rat model of OLT it was demonstrated that HO-1 overexpression after local adenoviral gene therapy impedes liver graft rejection by prevention of CD95L-mediated apoptosis, prolongs the allogeneic OLT survival and inhibits

Th-1 type cytokines via the downstream CO signaling pathway [140]. Likewise, the expression of HO-1 in human liver transplants was correlated to I/R injury and graft function [141]. In a study that investigated the levels of HO-1 in human livers before and after transplantation; human livers that initially had low HO-1 levels and increased HO-1 expression further had less injury and better hepatobiliary function than those with initially high HO-1 expression; thus an increase in HO-1 during transplantation is more protective than high HO-1 expression pre-transplantation [141]. In a clinical study of OLT, graft survival at 1 year was significantly better when the donor had the single nucleotide polymorphism A(-413)T genotype compared to TT-genotype corresponding to high and low HO-1 expression respectively [142]. Graft loss due to primary dysfunction occurred more frequently in TT-genotype compared to A-receivers [142]. Recipients of a liver with TT-genotype had significantly higher serum transaminases after transplantation and lower hepatic HO-1 mRNA levels compared to the A-allele livers [142].

HO-1 is also beneficial in liver fibrosis, a condition caused by activation of hepatic stellate cells (HSCs) resulting in a continuous wound healing response accompanied by inflammation and oxidative stress [143]. The severity of carbon tetrachloride (CCl₄)-induced micronodular fibrosis was reduced using adenovirus-mediated gene transfer where HSCs were targeted to overexpress HO-1 [68]. HO-1 overexpression in HSCs controls the fibrogenic activities associated with CCl₄-induced recurrent liver injury by impairing the proliferative ability of HSCs and reducing the transcript levels of type 1 collagen and transforming growth factor β 1 [68].

HO-1 is also protective in models of immune- and alcohol-mediated liver injury [139,144]. The immunologic cascade leading to liver damage can be studied with apoptotic liver damage models [145]. Upregulation of HO-1 by CoPP or adenoviral gene transfer protected mice from apoptotic liver damage induced by anti-CD95 antibody (ab) or D-galactosamine in combination with either anti-CD3 ab, LPS or TNF- α ; whereas HO-1 inhibition by SnPP abrogated the protective effect [144]. HO-1 mediated liver protection by reducing caspase-3 activation [144]. In addition, it was demonstrated that CO provided as a either gas, methylene chloride, or a CO-RMs, contributed to prevention of apoptotic liver injury in vivo [144]. CO in cooperation with biliverdin prolongs survival and reduces the expression of Th-1 inflammatory cytokines TNF- α and IFN- γ in immune-mediated liver injury [139]. Alcoholic liver disease (ALD) is characterized by a wide spectrum of liver pathology including steatosis and cirrhosis [146]. HO-1 induction in human primary hepatocytes by hemin and quercetin, a flavonoid with potent hepatoprotective effects, protects from ethanol-induced oxidative damage via the MAPK/Nrf2 pathway [147]. HO-1 inhibition by ZnPP or MAPK signaling transduction inhibitor(s) not only significantly blocked the protection of quercetin, but also promoted ethanol-induced cytotoxicity [147]. Furthermore it was determined that heme cleavage and CO release contributed to the protective effect through dose dependent inhibition of ethanol-induced cytochrome P450 2E1 (CYP 2E1) activity and hepatotoxicity [148].

Potential therapeutic challenges

Despite the array of evidence supporting the beneficial effects of HO-1 upregulation in diverse animal models of diseases of the gastrointestinal tract; the inability to induce or block HO-1 upregulation and activity in humans by genetic or pharmacological means under similar conditions still remains a challenge. The beneficial effect of HO-1 upregulation has been proven in animal models with HO-1 inhibitors such as the metalloporphyrins (SnPP, SnMP and ZnPP), which exacerbate disease state. Nevertheless there is not enough data to indicate that this is the case in humans. The data available on the use of metalloporphyrins in humans is on clinical studies that sought to inhibit HO-1 activity to treat excessive neonatal hyperbilirubinemia [149]. A comprehensive review on metalloporphyrins clinical studies by Schulz et al. reports transient erythema and photosensitization as common side effects [149]; however, there are no reports suggesting that gastrointestinal disorders manifest after HO-1 inhibition. The lack of attestation, by means of HO-1 inhibitors, that HO-1 upregulation is beneficial in the outcome of human disorders of the GI tract remains an area of further investigation. However recent data showing HO-1 polymorphism association with disease or disease severity lend support to the potential protective roles of HO-1 in humans. The upregulation of HO-1 protein and activity in humans has been demonstrated in a clinical study using intravenous hemin [150]. In the first reported human study; hemin which is normally used for the treatment of diseases involving porphyrin metabolism was able to induce HO-1 protein concentration and activity in healthy volunteers [150]. The increase in HO-1 expression did not increase venous carboxyhemoglobin concentrations or induce significant changes in hematological, biochemical or coagulation parameters and resulted in minimal adverse side effects such as headaches and vomiting reported in two out of the ten subjects [150]. This study suggests that HO-1 upregulation in humans is possible, yet a more detailed study assessing a dose response followed by hemin treatment is necessary due to the involvement of HO-1 a myriad of pathways. The modulation of HO-1 expression offers potential as a therapy for various human diseases but at the same time many impending side effects due to acute or chronic induction of HO-1, heme and the products of heme degradation. For instance free heme can activate the inflammatory cascade [151] and biliverdin/bilirubin and CO can be toxic at high levels in tissues. Biliverdin which is rapidly converted to bilirubin is neurotoxic in newborns resulting in kernicterus [152] and CO can affect hemostasis by having both anticoagulant and procoagulant functions [153]. Thus CO potential effects on coagulation is an important consideration for gastrointestinal diseases that are associated with vascular complication; for example venous or arterial thromboembolism are both well-recognized extraintestinal complications in IBD [154]. Thus an extensive assessment of the possible adverse effects should be carefully evaluated in order to determine the beneficial effects of HO-1 upregulation or its downstream effectors as therapy.

Conclusion

The HO-1 system plays an important role in many different pathways and its upregulation on different cell types is associated with the modulation of inflammatory diseases of the gastrointestinal tract (Figure 1). It is well established that HO-1 prevents oxidative stress by removal of excess heme; in addition HO-1 and heme degradation products work

synergistically or in conjunction to modulate and dampen inflammatory and cytotoxic responses. The data obtained in recent years have started to elucidate the mechanisms by which HO-1 protects the gastrointestinal tract from inflammation and oxidative injury. Therefore, the regulation of HO-1 by pharmacological means, at the gene or cellular level offers a potential new therapeutic target for inflammatory gastrointestinal diseases. Although the data in favor of this idea is compelling, HO-1 mode of action requires further investigation particularly in humans. Most of the studies supporting the protective role of HO-1 have been performed in animal models, thus a better understanding of HO-1 activity and regulation in human studies will likely allow efficient translation of the protective roles of HO-1 and bring forth potential HO-1 therapeutic targets for clinical use in gastrointestinal diseases.

Acknowledgments

This work was supported in part by the Robert Wood Johnson Foundation grant (to A.H.), the National Institutes of Health Grant DK092421 (to A.H.) and Digestive Disease Center grant DK56339 (to Stanford University).

References

1. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proceedings of the National Academy of Sciences of the United States of America. 1968; 61 (2):748. [PubMed: 4386763]
2. Kapitulnik J, Maines MD. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends in pharmacological sciences. 2009; 30 (3):129–137. [PubMed: 19217170]
3. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annual review of pharmacology and toxicology. 1997; 37 (1):517–554.
4. Mccoubrey WK, Huang T, Maines MD. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. European Journal of Biochemistry. 1997; 247 (2): 725–732. [PubMed: 9266719]
5. Elbirt KK, Bonkovsky HL. Heme oxygenase: recent advances in understanding its regulation and role. Proceedings of the Association of American Physicians. 1998; 111 (5):438–447. [PubMed: 10519165]
6. Trakshel G, Kutty R, Maines M. Purification and characterization of the major constitutive form of testicular heme oxygenase. The noninducible isoform. Journal of Biological Chemistry. 1986; 261 (24):11131–11137. [PubMed: 3525562]
7. Maines, MD. Heme oxygenase: clinical applications and functions. CRC Press; 1992.
8. Maines MD, Snyder R. New developments in the regulation of heme metabolism and their implications. CRC critical reviews in toxicology. 1984; 12 (3):241–314. [PubMed: 6378529]
9. Tsuji T, Kato A, Yasuda H, Miyaji T, Luo J, Sakao Y, Ito H, Fujigaki Y, Hishida A. The dimethylthiourea-induced attenuation of cisplatin nephrotoxicity is associated with the augmented induction of heat shock proteins. Toxicology and applied pharmacology. 2009; 234 (2):202–208. [PubMed: 18992762]
10. Umeda K, Takahashi T, Inoue K, Shimizu H, Maeda S, Morimatsu H, Omori E, Akagi R, Katayama H, Morita K. Prevention of hemorrhagic shock-induced intestinal tissue injury by glutamine via heme oxygenase-1 induction. Shock. 2009; 31 (1):40–49. [PubMed: 18497709]
11. Cooper KL, Liu KJ, Hudson LG. Enhanced ROS production and redox signaling with combined arsenite and UVA exposure: contribution of NADPH oxidase. Free Radical Biology and Medicine. 2009; 47 (4):381–388. [PubMed: 19414066]
12. Chang AY, Chan JY, Cheng H-L, Tsai C-Y, Chan SH. Hypoxia-inducible factor 1/heme oxygenase 1 cascade as upstream signals in the prolife role of heat shock protein 70 at rostral

- ventrolateral medulla during experimental brain stem death. *Shock*. 2009; 32 (6):651–658. [PubMed: 19333137]
13. Terry CM, Clikeman JA, Hoidal JR, Callahan KS. Effect of tumor necrosis factor- α and interleukin-1 α on heme oxygenase-1 expression in human endothelial cells. *American Journal of Physiology-Heart and Circulatory Physiology*. 1998; 274 (3):H883–H891.
 14. Niess AM, Passek F, Lorenz I, Schneider EM, Dickhuth H-H, Northoff H, Fehrenbach E. Expression of the antioxidant stress protein heme oxygenase-1 (HO-1) in human leukocytes: acute and adaptational responses to endurance exercise. *Free Radical Biology and Medicine*. 1999; 26 (1):184–192. [PubMed: 9890653]
 15. Nath KA, Balla G, Vercellotti GM, Balla J, Jacob HS, Levitt M, Rosenberg ME. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. *Journal of Clinical Investigation*. 1992; 90 (1):267. [PubMed: 1634613]
 16. Keyse SM, Applegate L, Tromvoukis Y, Tyrrell R. Oxidant stress leads to transcriptional activation of the human heme oxygenase gene in cultured skin fibroblasts. *Molecular and cellular biology*. 1990; 10 (9):4967–4969. [PubMed: 2388632]
 17. Applegate LA, Luscher P, Tyrrell RM. Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. *Cancer Research*. 1991; 51 (3):974–978. [PubMed: 1988141]
 18. Abraham NG, Rezzani R, Rodella L, Kruger A, Taller D, Volti GL, Goodman AI, Kappas A. Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes. *American Journal of Physiology-Heart and Circulatory Physiology*. 2004; 287 (6):H2468–H2477. [PubMed: 15284058]
 19. Otterbein LE, Bach FH, Alam J, Soares M, Lu HT, Wysk M, Davis RJ, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. *Nature medicine*. 2000; 6 (4):422–428.
 20. Petrache I, Otterbein LE, Alam J, Wiegand GW, Choi AM. Heme oxygenase-1 inhibits TNF- α -induced apoptosis in cultured fibroblasts. *American Journal of Physiology-Lung Cellular and Molecular Physiology*. 2000; 278 (2):L312–L319. [PubMed: 10666115]
 21. Lee T-S, Chau L-Y. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. *Nature medicine*. 2002; 8 (3):240–246.
 22. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. *Science*. 1987; 235 (4792):1043–1046. [PubMed: 3029864]
 23. Barañano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. *Proceedings of the National Academy of Sciences*. 2002; 99 (25):16093–16098.
 24. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. *Pediatrics*. 2004; 113 (6):1776–1782. [PubMed: 15173506]
 25. Nakao A, Otterbein LE, Overhaus M, Sarady JK, Tsung A, Kimizuka K, Nalesnik MA, Kaizu T, Uchiyama T, Liu F. Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. *Gastroenterology*. 2004; 127 (2):595–606. [PubMed: 15300591]
 26. Xue J, Nguyen DT, Habtezion A. Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis. *Gastroenterology*. 2012; 143 (6):1670–1680.10.1053/j.gastro.2012.08.051 [PubMed: 23022954]
 27. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton J, Vercellotti G. Ferritin: a cytoprotective antioxidant strategem of endothelium. *Journal of Biological Chemistry*. 1992; 267 (25):18148–18153. [PubMed: 1517245]
 28. Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS, Vercellotti GM. Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. *The American journal of pathology*. 1995; 147 (3):782. [PubMed: 7677189]
 29. Kapturczak MH, Wasserfall C, Brusko T, Campbell-Thompson M, Ellis TM, Atkinson MA, Agarwal A. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. *The American journal of pathology*. 2004; 165 (3):1045–1053. [PubMed: 15331427]
 30. Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. *Proceedings of the National Academy of Sciences*. 1997; 94 (20):10925–10930.

31. Tzima S, Victoratos P, Kranidioti K, Alexiou M, Kollias G. Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN- β production. *The Journal of experimental medicine*. 2009; 206 (5):1167–1179. [PubMed: 19398754]
32. True AL, Olive M, Boehm M, San H, Westrick RJ, Raghavachari N, Xu X, Lynn EG, Sack MN, Munson PJ. Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. *Circulation research*. 2007; 101 (9):893–901. [PubMed: 17885218]
33. Vachharajani TJ, Work J, Issekutz AC, Granger DN. Heme oxygenase modulates selectin expression in different regional vascular beds. *American Journal of Physiology-Heart and Circulatory Physiology*. 2000; 278 (5):H1613–H1617. [PubMed: 10775141]
34. Burnett AL, Johns DG, Kriegsfeld LJ, Klein SL, Calvin DC, Demas GE, Schramm LP, Tonegawa S, Nelson RJ, Snyder SH. Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2. *Nature medicine*. 1998; 4 (1):84–87.
35. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. *Journal of Clinical Investigation*. 1999; 103 (1):129–135. [PubMed: 9884342]
36. Radhakrishnan N, Yadav SP, Sachdeva A, Pruthi PK, Sawhney S, Piplani T, Wada T, Yachie A. Human heme oxygenase-1 deficiency presenting with hemolysis, nephritis, and asplenia. *Journal of pediatric hematology/oncology*. 2011; 33 (1):74–78. [PubMed: 21088618]
37. Igarashi K, Sun J. The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. *Antioxidants & redox signaling*. 2006; 8 (1–2):107–118. [PubMed: 16487043]
38. Jang JS, Piao S, Cha Y-N, Kim C. Taurine chloramine activates Nrf2, increases HO-1 expression and protects cells from death caused by hydrogen peroxide. *Journal of clinical biochemistry and nutrition*. 2009; 45 (1):37. [PubMed: 19590705]
39. De Backer O, Elinck E, Blanckaert B, Leybaert L, Motterlini R, Lefebvre RA. Water-soluble CO-releasing molecules reduce the development of postoperative ileus via modulation of MAPK/HO-1 signalling and reduction of oxidative stress. *Gut*. 2009; 58 (3):347–356. [PubMed: 19022916]
40. Salinas M, Wang J, Rosa de Sagarra M, Martín D, Rojo AI, Martín-Pérez J, Ortiz de Montellano PR, Cuadrado A. Protein kinase Akt/PKB phosphorylates heme oxygenase-1 in vitro and in vivo. *FEBS letters*. 2004; 578 (1):90–94. [PubMed: 15581622]
41. Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. *Free Radical Biology and Medicine*. 2004; 37 (8):1097–1104. [PubMed: 15451051]
42. Ono K, Mannami T, Iwai N. Association of a promoter variant of the haeme oxygenase-1 gene with hypertension in women. *Journal of hypertension*. 2003; 21 (8):1497–1503. [PubMed: 12872043]
43. Ono K, Goto Y, Takagi S, Baba S, Tago N, Nonogi H, Iwai N. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. *Atherosclerosis*. 2004; 173 (2):313–317.
44. Gulla A, Evans BJ, Navenot JM, Pundzius J, Barauskas G, Gulbinas A, Dambrauskas Z, Arafat H, Wang Z-X. Heme Oxygenase-1 Gene Promoter Polymorphism Is Associated With the Development of Necrotizing Acute Pancreatitis. *Pancreas*. 2014; 43 (8):1271–1276. [PubMed: 25036905]
45. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. *The American Journal of Human Genetics*. 2000; 66 (1):187–195.
46. Rueda B, Oliver J, Robledo G, López-Nevot MA, Balsa A, Pascual-Salcedo D, González-Gay MA, González-Escribano MF, Martín J. HO-1 promoter polymorphism associated with rheumatoid arthritis. *Arthritis & Rheumatism*. 2007; 56 (12):3953–3958. [PubMed: 18050210]
47. Schillinger M, Exner M, Minar E, Mlekusch W, Müllner M, Mannhalter C, Bach FH, Wagner O. Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. *Journal of the American College of Cardiology*. 2004; 43 (6):950–957. [PubMed: 15028349]

48. Chen Y-H, Lin S-J, Lin M-W, Tsai H-L, Kuo S-S, Chen J-W, Charng M-J, Wu T-C, Chen L-C, Ding P. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. *Human genetics*. 2002; 111 (1): 1–8. [PubMed: 12136229]
49. Immenschuh S, Tan M, Ramadori G. Nitric oxide mediates the lipopolysaccharide dependent upregulation of the heme oxygenase-1 gene expression in cultured rat Kupffer cells. *Journal of hepatology*. 1999; 30 (1):61–69. [PubMed: 9927151]
50. Bissell DM, Hammaker L, Schmid R. Liver sinusoidal cells Identification of a subpopulation for erythrocyte catabolism. *The Journal of cell biology*. 1972; 54 (1):107–119. [PubMed: 5038868]
51. Chauveau C, Rémy S, Royer PJ, Hill M, Tanguy-Royer S, Hubert F-X, Tesson L, Brion R, Beriour G, Gregoire M. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. *Blood*. 2005; 106 (5):1694–1702. [PubMed: 15920011]
52. Wijayanti N, Huber S, Samoylenko A, Kietzmann T, Immenschuh S. Role of NF- κ B and p38 MAP kinase signaling pathways in the lipopolysaccharide-dependent activation of heme oxygenase-1 gene expression. *Antioxidants & redox signaling*. 2004; 6 (5):802–810. [PubMed: 15345139]
53. Lin H-Y, Juan S-H, Shen S-C, Hsu F-L, Chen Y-C. Inhibition of lipopolysaccharide-induced nitric oxide production by flavonoids in RAW264. 7 macrophages involves heme oxygenase-1. *Biochemical pharmacology*. 2003; 66 (9):1821–1832. [PubMed: 14563492]
54. Rémy S, Blancou P, Tesson L, Tardif V, Brion R, Royer PJ, Motterlini R, Foresti R, Painchaud M, Pogu S. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. *The Journal of Immunology*. 2009; 182 (4):1877–1884. [PubMed: 19201840]
55. George JF, Braun A, Brusko TM, Joseph R, Bolisetty S, Wasserfall CH, Atkinson MA, Agarwal A, Kapturczak MH. Suppression by CD4+ CD25+ Regulatory T Cells is Dependent on Expression of Heme Oxygenase-1 in Antigen-Presenting Cells. *The American journal of pathology*. 2008; 173 (1):154–160. [PubMed: 18511516]
56. Moreau A, Hill M, Thebault P, Deschamps J, Chiffolleau E, Chauveau C, Moullier P, Anegón I, Alliot-Licht B, Cuturi M. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. *The FASEB Journal*. 2009; 23 (9):3070–3077.
57. Nakamichi I, Habtezion A, Zhong B, Contag CH, Butcher EC, Omary MB. Hemin-activated macrophages home to the pancreas and protect from acute pancreatitis via heme oxygenase-1 induction. *Journal of Clinical Investigation*. 2005; 115 (11):3007–3014. [PubMed: 16239966]
58. Wegiel B, Hedblom A, Li M, Gallo D, Csizmadia E, Harris C, Nemeth Z, Zuckerbraun B, Soares M, Persson JL. Heme oxygenase-1 derived carbon monoxide permits maturation of myeloid cells. *Cell death & disease*. 2014; 5 (3):e1139. [PubMed: 24651442]
59. Choi KM, Kashyap PC, Dutta N, Stoltz GJ, Ordog T, Shea Donohue T, Bauer AJ, Linden DR, Szurszewski JH, Gibbons SJ. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. *Gastroenterology*. 2010; 138 (7):2399–2409. e2391. [PubMed: 20178793]
60. Coëffier M, Le Pessot F, Leplingard A, Marion R, Lerebours E, Ducrotté P, Déchelotte P. Acute enteral glutamine infusion enhances heme oxygenase-1 expression in human duodenal mucosa. *The Journal of nutrition*. 2002; 132 (9):2570–2573. [PubMed: 12221210]
61. Barton S, Rampton D, Winrow V, Domizio P, Feakins R. Expression of heat shock protein 32 (hemoxygenase-1) in the normal and inflamed human stomach and colon: an immunohistochemical study. *Cell stress & chaperones*. 2003; 8 (4):329. [PubMed: 15115285]
62. Goda N, Suzuki K, Naito M, Takeoka S, Tsuchida E, Ishimura Y, Tamatani T, Suematsu M. Distribution of heme oxygenase isoforms in rat liver. Topographic basis for carbon monoxide-mediated microvascular relaxation. *Journal of Clinical Investigation*. 1998; 101 (3):604. [PubMed: 9449694]
63. Guo J, Cho C, Wang J, Koo M. Expression and immunolocalization of heat shock proteins in the healing of gastric ulcers in rats. *Scandinavian journal of gastroenterology*. 2002; 37 (1):17–22. [PubMed: 11858169]

64. Giri M, Erbil Y, Do ru-Abbaso lu S, Yanık BT, Alı H, Olgaç V, Toker GA. The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. *International journal of colorectal disease*. 2007; 22 (6):591–599. [PubMed: 17124609]
65. Paul G, Bataille F, Obermeier F, Bock J, Klebl F, Strauch U, Lochbaum D, Rümmele P, Farkas S, Schölmerich J. Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. *Clinical & Experimental Immunology*. 2005; 140 (3):547–555. [PubMed: 15932518]
66. Wang W, Guo X, Koo M, Wong B, Lam S, Ye Y, Cho C. Protective role of heme oxygenase-1 on trinitrobenzene sulfonic acid-induced colitis in rats. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2001; 281 (2):G586–G594. [PubMed: 11447040]
67. Takagi T, Naito Y, Mizushima K, Nukigi Y, Okada H, Suzuki T, Hirata I, Omatsu T, Okayama T, Handa O. Increased intestinal expression of heme oxygenase-1 and its localization in patients with ulcerative colitis. *Journal of Gastroenterology and Hepatology*. 2008; 23:S229–S233. [PubMed: 19120903]
68. Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, Farkas S, Xu R, Schlitt HJ, Fan ST. rAAV -mediated stable expression of heme oxygenase -1 in stellate cells: A new approach to attenuate liver fibrosis in rats. *Hepatology*. 2005; 42 (2):335–342. [PubMed: 16025519]
69. Werkström V, Ny L, Persson K, Andersson KE. Carbon monoxide-induced relaxation and distribution of haem oxygenase isoenzymes in the pig urethra and lower oesophagogastric junction. *British journal of pharmacology*. 1997; 120 (2):312–318. [PubMed: 9117125]
70. Ny L, Alm P, Ekström P, Larsson B, Grundemar L, Andersson KE. Localization and activity of haem oxygenase and functional effects of carbon monoxide in the feline lower oesophageal sphincter. *British journal of pharmacology*. 1996; 118 (2):392–399. [PubMed: 8735643]
71. Lillemoe K, Johnson L, Harmon J. Role of the components of the gastroduodenal contents in experimental acid esophagitis. *Surgery*. 1982; 92 (2):276–284. [PubMed: 6808683]
72. Kruel CRP, Pinto LFR, Blanco TCM, Barja-Fidalgo TC, Melo LL, Kruel CDP. Evaluation of the heme oxygenase-1 expression in esophagitis and esophageal cancer induced by different reflux experimental models and diethylnitrosamine. *Acta Cirurgica Brasileira*. 2010; 25 (3):304–310. [PubMed: 20498946]
73. Bjorkman D. Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. *The American journal of medicine*. 1998; 105 (5):17S–21S. [PubMed: 9855171]
74. Uc A, Zhu X, Wagner BA, Buettner GR, Berg DJ. Heme Oxygenase-1 Is Protective Against Nonsteroidal Anti-inflammatory Drug-induced Gastric Ulcers. *Journal of pediatric gastroenterology and nutrition*. 2012; 54 (4):471–476. [PubMed: 21873894]
75. Aburaya M, Tanaka K-I, Hoshino T, Tsutsumi S, Suzuki K, Makise M, Akagi R, Mizushima T. Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. *Journal of Biological Chemistry*. 2006; 281 (44):33422–33432. [PubMed: 16945925]
76. Cheng Y-T, Wu C-H, Ho C-Y, Yen G-C. Catechin protects against ketoprofen-induced oxidative damage of the gastric mucosa by up-regulating Nrf2 *in vitro* and *in vivo*. *The Journal of nutritional biochemistry*. 2013; 24 (2):475–483. [PubMed: 22704780]
77. Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y, Ichinose M. Polaprezinc (Zinc L-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1-a new mechanism of gastric mucosal protection. *Journal of pharmacological sciences*. 2009; 110 (3):285–294. [PubMed: 19542683]
78. Choi E-J, Oh H-M, Na B-R, Ramesh T, Lee H-J, Choi C-S, Choi S-C, Oh T-Y, Choi S-J, Chae J-R. Eupatilin protects gastric epithelial cells from oxidative damage and down-regulates genes responsible for the cellular oxidative stress. *Pharmaceutical research*. 2008; 25 (6):1355–1364. [PubMed: 18299966]
79. Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, Akagiri S, Adachi S, Handa O, Kokura S, Ichikawa H. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. *Journal of Pharmacology and Experimental Therapeutics*. 2009; 331 (1):255–264. [PubMed: 19628634]

80. Song HJ, Shin CY, Oh TY, Min YS, Park ES, Sohn UD. Eupatilin with heme oxygenase-1-inducing ability protects cultured feline esophageal epithelial cells from cell damage caused by indomethacin. *Biological and Pharmaceutical Bulletin*. 2009; 32 (4):589–596. [PubMed: 19336889]
81. Kadinov B, Itzev D, Gagov H, Christova T, Bolton T, Duridanova D. Induction of heme oxygenase in guinea-pig stomach: roles in contraction and in single muscle cell ionic currents. *Acta physiologica scandinavica*. 2002; 175 (4):297–313. [PubMed: 12167169]
82. Choi KM, Gibbons SJ, Nguyen TV, Stoltz GJ, Lurken MS, Ordog T, Szurszewski JH, Farrugia G. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. *Gastroenterology*. 2008; 135 (6):2055–2064. e2052. [PubMed: 18926825]
83. Takagi T, Naito Y, Mizushima K, Nukigi Y, Okada H, Suzuki T, Hirata I, Omatsu T, Okayama T, Handa O. Increased intestinal expression of heme oxygenase-1 and its localization in patients with ulcerative colitis. *Journal of gastroenterology and hepatology*. 2008; 23 (s2):S229–S233. [PubMed: 19120903]
84. Higuchi K, Yoda Y, Amagase K, Kato S, Tokioka S, Murano M, Takeuchi K, Umegaki E. Prevention of NSAID-induced small intestinal mucosal injury: prophylactic potential of lansoprazole. *Journal of clinical biochemistry and nutrition*. 2009; 45 (2):125. [PubMed: 19794918]
85. Yoda Y, Amagase K, Kato S, Tokioka S, Murano M, Kakimoto K, Nishio H, Umegaki E, Takeuchi K, Higuchi K. Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. *Journal of Physiology and Pharmacology*. 2010; 61 (3):287. [PubMed: 20610858]
86. Yeh CT, Chiu HF, Yen GC. Protective effect of sulforaphane on indomethacin -induced cytotoxicity via heme oxygenase-1 expression in human intestinal Int 407 cells. *Molecular nutrition & food research*. 2009; 53 (9):1166–1176. [PubMed: 19653226]
87. Chung SW, Liu X, Macias AA, Baron RM, Perrella MA. Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. *Journal of Clinical Investigation*. 2008; 118 (1):239–247. [PubMed: 18060048]
88. Tamion F, Richard V, Lacoume Y, Thuillez C. Intestinal preconditioning prevents systemic inflammatory response in hemorrhagic shock. Role of HO-1. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2002; 283 (2):G408–G414. [PubMed: 12121889]
89. Attuwaybi B, Kozar R, Moore-Olufemi S, Sato N, Hassoun H, Weisbrodt N, Moore F. Heme oxygenase-1 induction by hemin protects against gut ischemia/reperfusion injury. *Journal of Surgical Research*. 2004; 118 (1):53–57. [PubMed: 15093717]
90. Mallick IH, Winslet MC, Seifalian AM. Ischemic preconditioning of small bowel mitigates the late phase of reperfusion injury: heme oxygenase mediates cytoprotection. *The American Journal of Surgery*. 2010; 199 (2):223–231.
91. Wasserberg N, Pileggi A, Salgar SK, Ruiz P, Ricordi C, Inverardi L, Tzakis AG. Heme oxygenase-1 upregulation protects against intestinal ischemia/reperfusion injury: a laboratory based study. *International journal of surgery*. 2007; 5 (4):216–224. [PubMed: 17660127]
92. Tamaki, T.; Konoeda, Y.; Yasuhara, M.; Tanaka, M.; Yokota, N.; Hayashi, T.; Katori, M.; Uchida, Y.; Kawamura, A. Transplantation proceedings. Vol. 1. Elsevier; 1999. Glutamine-induced heme oxygenase-1 protects intestines and hearts from warm ischemic injury; p. 1018-1019.
93. Mallick IH, Yang W-X, Winslet MC, Seifalian AM. Pyrrolidine dithiocarbamate reduces ischemia-reperfusion injury of the small intestine. *World Journal of Gastroenterology*. 2005; 11 (46):7308. [PubMed: 16437633]
94. Yoshida T, Maulik N, Ho Y-S, Alam J, Das DK. Hmox-1 Constitutes an Adaptive Response to Effect Antioxidant Cardioprotection A Study With Transgenic Mice Heterozygous for Targeted Disruption of the Heme Oxygenase-1 Gene. *Circulation*. 2001; 103 (12):1695–1701. [PubMed: 11273999]
95. Liu X, Wei J, Peng DH, Layne MD, Yet S-F. Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice. *Diabetes*. 2005; 54 (3):778–784. [PubMed: 15734856]

96. Yano Y, Ozono R, Oishi Y, Kambe M, Yoshizumi M, Ishida T, Omura S, Oshima T, Igarashi K. Genetic ablation of the transcription repressor Bach1 leads to myocardial protection against ischemia/reperfusion in mice. *Genes to Cells*. 2006; 11 (7):791–803. [PubMed: 16824198]
97. Scott JR, Cukiernik MA, Ott MC, Bihari A, Badhwar A, Gray DK, Harris KA, Parry NG, Potter RF. Low-dose inhaled carbon monoxide attenuates the remote intestinal inflammatory response elicited by hindlimb ischemia-reperfusion. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2009; 296 (1):G9–G14. [PubMed: 19114681]
98. Nakao A, Kaczorowski DJ, Sugimoto R, Billiar TR, McCurry KR. Application of heme oxygenase-1, carbon monoxide and biliverdin for the prevention of intestinal ischemia/reperfusion injury. *Journal of clinical biochemistry and nutrition*. 2008; 42 (2):78. [PubMed: 18385824]
99. Nakao A, Kimizuka K, Stolz DB, Neto JS, Kaizu T, Choi AM, Uchiyama T, Zuckerbraun BS, Nalesnik MA, Otterbein LE. Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. *The American journal of pathology*. 2003; 163 (4):1587–1598. [PubMed: 14507665]
100. Fondevila C, Shen XD, Tsuchiyashi S, Yamashita K, Csizmadia E, Lassman C, Busuttill RW, Kupiec-Weglinski JW, Bach FH. Biliverdin therapy protects rat livers from ischemia and reperfusion injury. *Hepatology*. 2004; 40 (6):1333–1341. [PubMed: 15565657]
101. Yun KJ, Choi SC, Oh JM. Expression of heme oxygenase-1 in ischemic colitis. *The Korean journal of gastroenterology= Taehan Sohwagi Hakhoe chi*. 2005; 45 (5):335–339. [PubMed: 15908766]
102. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflammatory bowel diseases*. 2000; 6 (1):8–15. [PubMed: 10701144]
103. Naito Y, Takagi T, Yoshikawa T. Heme oxygenase-1: a new therapeutic target for inflammatory bowel disease. *Alimentary pharmacology & therapeutics*. 2004; 20:177–184. [PubMed: 15298625]
104. Zhong W, Xia Z, Hinrichs D, Rosenbaum JT, Wegmann KW, Meyrowitz J, Zhang Z. Hemin Exerts Multiple Protective Mechanisms and Attenuates Dextran Sulfate Sodium-induced Colitis. *Journal of pediatric gastroenterology and nutrition*. 2010; 50 (2):132–139. [PubMed: 20081544]
105. Varga C, Laszlo F, Fritz P, Cavicchi M, Lamarque D, Horvath K, Posa A, Berko A, Whittle BJ. Modulation by heme and zinc protoporphyrin of colonic heme oxygenase-1 and experimental inflammatory bowel disease in the rat. *European journal of pharmacology*. 2007; 561 (1):164–171. [PubMed: 17292349]
106. Berberat PO, Yamashita K, Warny MM, Csizmadia E, Robson SC, Bach FH. Heme oxygenase -1-generated biliverdin ameliorates experimental murine colitis. *Inflammatory bowel diseases*. 2005; 11 (4):350–359. [PubMed: 15803024]
107. Khor TO, Huang M-T, Kwon KH, Chan JY, Reddy BS, Kong A-N. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. *Cancer Research*. 2006; 66 (24):11580–11584. [PubMed: 17178849]
108. Harusato A, Naito Y, Takagi T, Uchiyama K, Mizushima K, Hirai Y, Higashimura Y, Katada K, Handa O, Ishikawa T. BTB and CNC homolog 1 (Bach1) deficiency ameliorates TNBS colitis in mice: role of M2 macrophages and heme oxygenase-1. *Inflammatory bowel diseases*. 2013; 19 (4):740–753. [PubMed: 23446334]
109. Hegazi RA, Rao KN, Mayle A, Sepulveda AR, Otterbein LE, Plevy SE. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. *The Journal of experimental medicine*. 2005; 202 (12):1703–1713. [PubMed: 16365149]
110. Sheikh SZ, Hegazi RA, Kobayashi T, Onyiah JC, Russo SM, Matsuoka K, Sepulveda AR, Li F, Otterbein LE, Plevy SE. An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. *The Journal of Immunology*. 2011; 186 (9):5506. [PubMed: 21444764]
111. Horváth K, Varga C, Berkó A, Pósa A, László F, Whittle BJ. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. *European journal of pharmacology*. 2008; 581 (3):315–323. [PubMed: 18215658]

112. Schulz S, Wong RJ, Jang KY, Kalish F, Chisholm KM, Zhao H, Vreman HJ, Sylvester KG, Stevenson DK. Heme oxygenase-1 deficiency promotes the development of necrotizing enterocolitis-like intestinal injury in a newborn mouse model. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2013; 304 (11):G991–G1001. [PubMed: 23578787]
113. Santulli TV, Schullinger JN, Heird WC, Gongaware RD, Wigger J, Barlow B, Blanc WA, Berdon WE. Acute necrotizing enterocolitis in infancy: a review of 64 cases. *Pediatrics*. 1975; 55 (3): 376–387. [PubMed: 1143976]
114. Yeoh E, Horowitz M. Radiation enteritis. *Surgery, gynecology & obstetrics*. 1987; 165 (4):373–379.
115. Giri M, Erbil Y, Öztezcan S, Olgaç V, Barbaros U, Deveci U, Kirgiz B, Uysal M, Toker GA. The effect of heme oxygenase-1 induction by glutamine on radiation-induced intestinal damage: the effect of heme oxygenase-1 on radiation enteritis. *The American journal of surgery*. 2006; 191 (4):503–509.
116. Wang J, Zheng H, Sung C-C, Hauer-Jensen M. The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. *International Journal of Radiation Oncology* Biology* Physics*. 1999; 45 (5):1289–1296.
117. Abbaso lu SD, Erbil Y, Eren T, Giri M, Barbaros U, Yücel R, Olgaç V, Uysal M, Toker G. The effect of heme oxygenase-1 induction by octreotide on radiation enteritis. *Peptides*. 2006; 27 (6): 1570–1576. [PubMed: 16375990]
118. Xue J, Sharma V, Habtezion A. Immune cells and immune-based therapy in pancreatitis. *Immunol Res*. 2014; 58 (2–3):378–386.10.1007/s12026-014-8504-5 [PubMed: 24710635]
119. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology*. 2013; 144 (6):1252–1261.10.1053/j.gastro.2013.01.068 [PubMed: 23622135]
120. Sarles H. Etiopathogenesis and definition of chronic pancreatitis. *Dig Dis Sci*. 1986; 31 (9 Suppl): 91S–107S. [PubMed: 3525051]
121. Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. *Gastroenterology*. 2013; 144 (6):1230–1240.10.1053/j.gastro.2012.12.042 [PubMed: 23622132]
122. Nuhn P, Mitkus T, Ceyhan GO, Kunzli BM, Bergmann F, Fischer L, Giese N, Friess H, Berberat PO. Heme oxygenase 1-generated carbon monoxide and biliverdin attenuate the course of experimental necrotizing pancreatitis. *Pancreas*. 2013; 42 (2):265–271.10.1097/MPA.0b013e318264cc8b [PubMed: 23000891]
123. Xue J, Habtezion A. Carbon monoxide-based therapy ameliorates acute pancreatitis via TLR4 inhibition. *J Clin Invest*. 2014; 124 (1):437–447.10.1172/JCI71362 [PubMed: 24334457]
124. Sato H, Siow RC, Bartlett S, Taketani S, Ishii T, Bannai S, Mann GE. Expression of stress proteins heme oxygenase-1 and -2 in acute pancreatitis and pancreatic islet betaTC3 and acinar AR42J cells. *FEBS Lett*. 1997; 405 (2):219–223. [PubMed: 9089294]
125. Habtezion A, Kwan R, Yang AL, Morgan ME, Akhtar E, Wanaski SP, Collins SD, Butcher EC, Kamal A, Omary MB. Heme oxygenase-1 is induced in peripheral blood mononuclear cells of patients with acute pancreatitis: a potential therapeutic target. *Am J Physiol Gastrointest Liver Physiol*. 2011; 300 (1):G12–20.10.1152/ajpgi.00231.2010 [PubMed: 20966033]
126. Nakamichi I, Habtezion A, Zhong B, Contag CH, Butcher EC, Omary MB. Hemin-activated macrophages home to the pancreas and protect from acute pancreatitis via heme oxygenase-1 induction. *J Clin Invest*. 2005; 115 (11):3007–3014.10.1172/JCI24912 [PubMed: 16239966]
127. Habtezion A, Kwan R, Akhtar E, Wanaski SP, Collins SD, Wong RJ, Stevenson DK, Butcher EC, Omary MB. Panhematin provides a therapeutic benefit in experimental pancreatitis. *Gut*. 2011; 60 (5):671–679.10.1136/gut.2010.217208 [PubMed: 21159893]
128. Zhang F, Fei J, Zhao B, Chen E, Mao E. Protective Effect of Adenoviral Transfer of Heme Oxygenase-1 Gene on Rats With Severe Acute Pancreatitis. *Am J Med Sci*. 2014; 1097/MAJ.0000000000000225
129. Gordon S. Alternative activation of macrophages. *Nat Rev Immunol*. 2003; 3 (1):23–35.10.1038/nri978 [PubMed: 12511873]

130. Chen P, Sun B, Chen H, Wang G, Pan S, Kong R, Bai X, Wang S. Effects of carbon monoxide releasing molecule-liberated CO on severe acute pancreatitis in rats. *Cytokine*. 2010; 49 (1):15–23.10.1016/j.cyto.2009.09.013 [PubMed: 19900821]
131. Omary MB, Lugea A, Lowe AW, Pandol SJ. The pancreatic stellate cell: a star on the rise in pancreatic diseases. *J Clin Invest*. 2007; 117 (1):50–59.10.1172/JCI30082 [PubMed: 17200706]
132. Schwer CI, Guerrero AM, Humar M, Roesslein M, Goebel U, Stoll P, Geiger KK, Pannen BH, Hoetzel A, Schmidt R. Heme oxygenase-1 inhibits the proliferation of pancreatic stellate cells by repression of the extracellular signal-regulated kinase1/2 pathway. *J Pharmacol Exp Ther*. 2008; 327 (3):863–871.10.1124/jpet.108.136549 [PubMed: 18784349]
133. Schwer CI, Mutschler M, Stoll P, Goebel U, Humar M, Hoetzel A, Schmidt R. Carbon monoxide releasing molecule-2 inhibits pancreatic stellate cell proliferation by activating p38 mitogen-activated protein kinase/heme oxygenase-1 signaling. *Mol Pharmacol*. 2010; 77 (4):660–669.10.1124/mol.109.059519 [PubMed: 20053955]
134. Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen X-D, Zhao D, Zaky J, Melinek J, Lassman CR. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. *The Journal of clinical investigation*. 1999; 104 (11):1631–1639. [PubMed: 10587527]
135. Ben-Ari Z, Issan Y, Katz Y, Sultan M, Safran M, Michal L-S, Nader GA, Kornowski R, Grief F, Pappo O. Induction of heme oxygenase-1 protects mouse liver from apoptotic ischemia/reperfusion injury. *Apoptosis*. 2013; 18 (5):547–555. [PubMed: 23435964]
136. Wang Y, Shen J, Xiong X, Xu Y, Zhang H, Huang C, Tian Y, Jiao C, Wang X, Li X. Remote Ischemic Preconditioning Protects against Liver Ischemia-Reperfusion Injury via Heme Oxygenase-1-Induced Autophagy. *PloS one*. 2014; 9 (6):e98834. [PubMed: 24914543]
137. Carchman EH, Rao J, Loughran PA, Rosengart MR, Zuckerbraun BS. Heme oxygenase-1-mediated autophagy protects against hepatocyte cell death and hepatic injury from infection/sepsis in mice. *Hepatology*. 2011; 53 (6):2053–2062. [PubMed: 21437926]
138. Starzl TE, Demetris AJ. Liver transplantation: A 31-year perspective part III. Current problems in surgery. 1990; 27 (4):187–240.
139. Sass G, Seyfried S, Parreira Soares M, Yamashita K, Kaczmarek E, Neuhuber WL, Tiegs G. Cooperative effect of biliverdin and carbon monoxide on survival of mice in immune-mediated liver injury. *Hepatology*. 2004; 40 (5):1128–1135. [PubMed: 15486963]
140. Ke B, Buelow R, Shen X-D, Melinek J, Amersi F, Gao F, Ritter T, Volk H-D, Busuttill RW, Kupiec-Weglinski JW. Heme oxygenase 1 gene transfer prevents CD95/Fas ligand-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway. *Human gene therapy*. 2002; 13 (10):1189–1199. [PubMed: 12133272]
141. Geuken E, Buis CI, Visser DS, Blokzijl H, Moshage H, Nemes B, Leuvenink HG, De Jong KP, Peeters PM, Slooff MJ. Expression of Heme Oxygenase -1 in Human Livers Before Transplantation Correlates with Graft Injury and Function After Transplantation. *American journal of transplantation*. 2005; 5 (8):1875–1885. [PubMed: 15996234]
142. Buis CI, van der Steege G, Visser DS, Nolte IM, Hepkema BG, Nijsten M, Slooff MJ, Porte RJ. Heme Oxygenase-1 Genotype of the Donor Is Associated With Graft Survival After Liver Transplantation. *American Journal of Transplantation*. 2008; 8 (2):377–385. [PubMed: 18093274]
143. Flier JS, Underhill LH, Friedman SL. The Cellular Basis of Hepatic Fibrosis--Mechanisms and Treatment Strategies. *New England Journal of Medicine*. 1993; 328 (25):1828–1835. [PubMed: 8502273]
144. Sass G, Soares MCP, Yamashita K, Seyfried S, Zimmermann WH, Eschenhagen T, Kaczmarek E, Ritter T, Volk HD, Tiegs G. Heme oxygenase-1 and its reaction product, carbon monoxide, prevent inflammation-related apoptotic liver damage in mice. *Hepatology*. 2003; 38 (4):909–918. [PubMed: 14512878]
145. Wendela A. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF- α .
146. Dey A, Cederbaum AI. Alcohol and oxidative liver injury. *Hepatology*. 2006; 43 (S1):S63–S74. [PubMed: 16447273]

147. Yao P, Nussler A, Liu L, Hao L, Song F, Schirmeier A, Nussler N. Quercetin protects human hepatocytes from ethanol-derived oxidative stress by inducing heme oxygenase-1 via the MAPK/Nrf2 pathways. *Journal of hepatology*. 2007; 47 (2):253–261. [PubMed: 17433488]
148. Yao P, Hao L, Nussler N, Lehmann A, Song F, Zhao J, Neuhaus P, Liu L, Nussler A. The protective role of HO-1 and its generated products (CO, bilirubin, and Fe) in ethanol-induced human hepatocyte damage. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2009; 296 (6):G1318–G1323. [PubMed: 19325051]
149. Schulz S, Wong RJ, Vreman HJ, Stevenson DK. Metalloporphyrins - An Update. *Frontiers in pharmacology*. 2012; 3
150. Bharucha AE, Kulkarni A, Choi KM, Camilleri M, Lempke M, Brunn GJ, Gibbons SJ, Zinsmeister AR, Farrugia G. First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans. *Clinical Pharmacology & Therapeutics*. 2009; 87 (2):187–190. [PubMed: 19956091]
151. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. *Pharmacological reviews*. 2008; 60 (1):79–127. [PubMed: 18323402]
152. Kappas A. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. *Pediatrics*. 2004; 113 (1):119–123. [PubMed: 14702459]
153. Nielsen VG, Pretorius E. Carbon monoxide: Anticoagulant or procoagulant? *Thrombosis research*. 2014; 133 (3):315–321. [PubMed: 24360115]
154. Bagen JA, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. *Archives of Internal Medicine*. 1936; 58 (1):17–31.

Figure 1.

Hemeoxygenase-1 (HO-1) induction has a protective role in the gastrointestinal (GI) system. Up-regulation of HO-1 and/or its downstream effectors in different cells and tissues is associated with protection against oxidative stress and tissue injury. AhR, aryl hydrocarbon receptor; Bach1, heme binding protein; BVR, biliverdin reductase; CoPP, cobalt protoporphyrin; DC, dendritic cells; HO-1, hemeoxygenase-1; iNOS, inducible nitric oxide synthase; MΦs, macrophages; NOS, nitric oxide synthase; Nrf2, nuclear erythroid 2-related factor-2; SnMP, tin mesoporphyrin; SnPP, tin protoporphyrin; ZnPP, zinc protoporphyrin.